Reviewing Immune Pharmaceuticals (IMNP) and Pfizer (PFE)

Immune Pharmaceuticals (NASDAQ: IMNP) and Pfizer (NYSE:PFE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Insider & Institutional Ownership

1.6% of Immune Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.8% of Pfizer shares are owned by institutional investors. 3.9% of Immune Pharmaceuticals shares are owned by company insiders. Comparatively, 0.1% of Pfizer shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.


This table compares Immune Pharmaceuticals and Pfizer’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Immune Pharmaceuticals N/A -1,443.76% -117.17%
Pfizer 18.69% 25.41% 8.90%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Immune Pharmaceuticals and Pfizer, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immune Pharmaceuticals 0 0 0 0 N/A
Pfizer 1 5 10 0 2.56

Pfizer has a consensus price target of $38.60, suggesting a potential upside of 6.60%. Given Pfizer’s higher possible upside, analysts plainly believe Pfizer is more favorable than Immune Pharmaceuticals.

Valuation and Earnings

This table compares Immune Pharmaceuticals and Pfizer’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Immune Pharmaceuticals N/A N/A -$32.66 million ($4.20) -0.13
Pfizer $52.82 billion 4.09 $7.22 billion $1.62 22.35

Pfizer has higher revenue and earnings than Immune Pharmaceuticals. Immune Pharmaceuticals is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.


Pfizer pays an annual dividend of $1.28 per share and has a dividend yield of 3.5%. Immune Pharmaceuticals does not pay a dividend. Pfizer pays out 79.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has increased its dividend for 7 consecutive years.

Risk & Volatility

Immune Pharmaceuticals has a beta of 2.04, meaning that its stock price is 104% more volatile than the S&P 500. Comparatively, Pfizer has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500.


Pfizer beats Immune Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

Immune Pharmaceuticals Company Profile

Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.

Pfizer Company Profile

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

Receive News & Ratings for Immune Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply